Clinical trial · Interventional
Childhood B-acute Lymphoblastic Leukaemia and Role of CD9 Gene Regulation in Relapse
REALL CD9 : Molecular Mechanisms Involved in Relapses of Childhood B-acute Lymphoblastic Leukaemia, Role of Non-coding RNA in CD9 Gene Regulation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
B-acute lymphoblastic leukaemia (B-ALL) is the most common cancer in children, with 20% of patients relapsing. CD9, a transmembrane protein, is linked to the migratory and adhesion capacities of leukaemia cells and could be associated with relapses. The aim of this project is to understand how CD9 regulation can be a marker of potential relapses, using bone and blood sampling of newly diagnosed patients at 3 crucial moments of therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphoblastic, Acute, Pediatric | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sampling bone tissue and blood | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients
- description
- All included patients. Bone and blood sampling
- interventionNames
- Other: Sampling bone tissue and blood
Primary outcomes (1)
- measure
- Non coding RNA network in CD9 regulation
- timeFrame
- 5 years
- description
- description of the network of lncRNAs (circRNAs/miRNAs) involved in the regulation of CD9 present on the surface of blasts at the time of diagnosis of B-ALL (nature of the lncRNAs, level of expression, etc.)
Secondary outcomes (2)
- measure
- Non coding RNA network in CD9 regulation as a prognosis factor of disease follow-up
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 17 Years
Show eligibility criteria text
Inclusion Criteria: * Under 18 years * With established diagnosis of B-ALL * Initial diagnosis made in the investigating centre * Having received oral and written information about the protocol, or oral only if the patient is unable to read. * Having signed a consent form if the patient is capable of giving informed written consent. * Whose legal guardians have received oral and written information about the protocol, and have signed a free, informed and written consent. * Beneficiary of a social security scheme Exclusion Criteria: * Isolated extramedullary involvement at inclusion * Patient of childbearing age without effective contraception. * Adult subject to legal protection (safeguard of justice, curatorship, guardianship), person deprived of liberty.
References
Publications (0)
Data not yet available